• In Canada and Brazil, ETST is lab testing three new cannabidiol formulations, developing two more CBD products and conducting studies on its Hygee device for women
• In the U.S., it is researching CBD’s impact on breast cancer and immune cells
• ETST is focused on the development of innovative products to reach its goal of becoming a world leader in the CBD space, with three new CBD formulas being developed under a provisory patent

Earth Science Tech, Inc. (OTC: ETST) is testing in Canada and Brazil a diverse mix of cannabidiol (CBD) formulations, including a superfood formula (http://ibn.fm/0y5lu). It is also conducting pre-launch lab studies of a medical device scheduled to be marketed internationally (http://ibn.fm/8iIOO).

ETST is a biotech company based in Doral, Florida, marketing and developing CBD products for the pharmaceutical and nutraceutical fields. The company manufactures, markets and distributes its own cannabinoid products, including capsules and oils. ETST has revamped its line of CBD products and will extend its line of raw dark chocolates with three new flavors in conjunction with joint venture partner Karmavore Superfoods. An anticipated launch is planned for the third quarter of 2018 (http://ibn.fm/aM8s0).

In Canada, the company is testing three new CBD IP formulations. They include a neuron protector and a breast protector. R&D is being conducted by the Centre de Developpement bioalimentaire du Quebec (CDBQ) or Quebec Agrifood Innovation Center (QAIC). An additional formulation will include a natural protective agent that will extend shelf life. A third product is a superfood that includes a mix of hemp oil and a highly potent antioxidant. In Quebec, the company is also clinically testing its Hygee MSN-2 medical device for detection of sexually transmitted infections (STIs) in women at the Clinique Santé Amitié.

ETST is developing two new products in Brazil through a joint venture with Bionatus Laboratrio Botnico of Brazil and its Canadian division, Bionatus Botanical Laboratories, Inc. The products are Propovit, enriched with ETST hemp oil, and a reformulation of Bionatus’ product featuring CBD.

In the U.S., it is conducting studies with the University of Central Oklahoma of high grade full spectrum CBD on breast cancer and immune cells.

ETST holds several wholly owned subsidiaries. Cannabis Therapeutics is an emerging biotechnology company. KannaBidioiD manufactures and distributes in the recreational sector. Earth Science Foundation, Inc., is becoming a non-profit and accepts grants and donations to conduct additional studies. Earth Science Pharmaceutical develops medical diagnostic tools and vaccines. ETST also recently formed subsidiary Canno Inno Laboratories Inc., a strategic Montreal, Canada-based company that provides ETST with access to government grants.

For more information, visit the company’s website at www.EarthScienceTech.com

• Incentivized gaming apps generate data and analytics that add new customers, stimulate sales, build brand loyalty and offer retailers a better understanding of their audiences
• Strategy aims to convert unknown social media followers into identified email subscribers through games and surveys, thereby establishing a platform that drives revenue and branding
• 2018 goals include the debut of enhanced paid version of its Gamify slide out app; company also plans an in-store product launch in February 2019

DeepMarkit Inc. (TSX.V: MKT) (OTCQB: MKTDF) utilizes the marriage of game-like features to a non-game platform to develop gamification marketing. The result is collection of consumer data from online games. The application of real-time analytics is performed, and information is created for retailers to better understand their customer audiences (http://ibn.fm/XPT3H). MKTDF’s adaptable gamification app for online customers can be used on the Shopify, Inc. platform (NYSE: SHOP) (http://ibn.fm/6jlFe).

MKTDF is focusing on this strategy in a gamification market that’s projected to reach $22.9 billion by 2022, growing at a CAGR of 41.8 percent from 2014-2022, according to P&S Market Research (http://ibn.fm/J6blm). These are online games for business purposes, the company says. The goals are leads, product promotions, brand building and more sales.

MKTDF is planning a second half 2018 launch for its enhanced Gamify paid slide out app from the current free version, available on multiple e-commerce platforms. It is also readying the debut of its survey product by year-end, as noted in the company’s June 2018 investor presentation (http://ibn.fm/VW3fQ). In addition, it is planning an in-store product launch in February 2019.

MKTDF is a Canada-based technology company focused on the monetization of gamification. It seeks, through incentivized gaming apps, to convert visitors to loyal customers who confirm their identities as they participate. Increasing the conversion rate by only one percent can double revenue, MKTDF’s presentation says. MKTDF’s revenue comes from a three-tiered pricing program per campaign.

The company’s proprietary technology platform is patent-pending, and MKTDF says that it represents the only publicly-listed firm focused on gamification. The company’s aim is to capture, through gamification, the interest of individuals who wish to earn prizes and discounts through its branded digital games. This results in the creation of loyal customers and increased branding as visitors are converted. MKTDF offers investors the opportunity to become involved in gamification as a monetized tool for businesses to promote products, generate leads and drive sales.

Darold Parken, CEO and president of MKTDF, says in a corporate investor video that the company’s markets are international and its ambitions are global (http://ibn.fm/jOi2O). The company believes that a growing passion in the Asia-Pacific region for gaming is creating a major opportunity for global gamification growth. MKTDF explains that China and India, together, are projected in a study by U.S. media agency Zenith to have nearly two billion smartphone users in 2018.

For more information, visit the company’s website at www.DeepMarkit.com

• Petroteq is developing the first-ever environmentally friendly oil sands mining facility
• The company’s Asphalt Ridge facility is located in close proximity to major oil refineries in Utah, giving Petroteq’s heavy oil product great market potential
• Petroteq has 2,541 leased acres and 87.49 million barrels of mineable oil sands and expects to increase its output to 5,000-8,000 barrels of oil per day by late 2020 or early 2021

Focused on operating the first-ever environmentally friendly oil sands mining facility, fully integrated oil and gas company Petroteq Energy Inc. (TSX.V: PQE) (OTC: PQEFF) (FSE: PQCF) recently announced that it has finalized continuity testing at its Asphalt Ridge facility in Utah’s Uintah Basin and is making final arrangements for continuous operations and marketing activities (http://ibn.fm/AbdIl).

Petroteq’s focus is on a new proprietary, patented, environmentally safe and sustainable technology for extracting heavy oils from oil sands, oil shale deposits and shallow oil deposits. The company is engaged in developing and implementing its innovative heavy oil processing and extraction technologies, which produce zero greenhouse gases, produce no waste, use no water and require no high temperatures. The Asphalt Ridge extraction facility comprises 10 stages containing a total of 14 operating processes.

The site operations and field teams at the Asphalt Ridge facility have been working hard to expand the site’s production capacity and to bring the facility to operational status. The company’s onsite team includes U.S. Armed Forces veterans, Native Americans and local workers from the Uintah Basin.

The pricing and structure of Petroteq’s sales production and marketing strategy for the Asphalt Ridge site are not yet finalized, but the company’s management is confident that its operational costs and related discounts will be much lower than the current discount on heavy crude oil from Canada, which recently hit close to a five-year high. With pipelines at capacity and refining customers going offline for seasonal maintenance, the discount is expected to remain high.

Petroteq believes that its heavy oil product has promising market potential, as the company’s Asphalt Ridge Facility is located in close proximity to major oil refineries in Utah. The company anticipates pricing to closely track that of West Texas Intermediate, as refiners are already accustomed to purchasing and using Utah heavy oil as part of their refining mixes.

As Petroteq progresses in its operational activities, primary aspects of the company’s operations and proprietary solvent processes are being reviewed and vetted by company president and Director Dr. Jerry Bailey, and by company CTO Vladimir Podlipskiy. A great deal of new equipment has been added to the enhanced Asphalt Ridge facility, and the company is finding opportunities to refine its techniques for more efficient production.

The operational preparedness of the Asphalt Ridge facility coincides with the laboratory testing that Petroteq has been conducting. Multiple samples have been taken from the company’s mining operations, and Petroteq has determined the proprietary solvent molecular and volumetric specifications needed to efficiently and effectively work with its extraction process. Petroteq is also considering various new and compelling products that will work with and integrate with its proprietary solvent process to improve separation of oil from sand and to stabilize and mitigate asphaltenes in the oil, resulting in the production of an improved grade of heavy oil.

To date, Petroteq boasts 2,541 leased acres and 87.49 million barrels of mineable oil sands. The company expects to boost its output to the point of producing 5,000 to 8,000 barrels of oil per day by late 2020 or early 2021 (http://ibn.fm/5V1k6).

In addition to its proprietary heavy oil extraction technologies, Petroteq is also developing the very first blockchain-based platform created exclusively to meet the supply chain needs of the oil and gas sector. Being developed through PetroBLOQ, LLC, Petroteq’s wholly owned subsidiary, this platform works hand-in-hand with Petroteq’s production system to ensure efficiency.

For more information, visit the company’s website at www.Petroteq.energy

• Private placement of $4.9 million in June 2018
• Five R&D programs currently underway
• Preventative health care market set to reach $200 billion by 2025

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is on a mission neatly expressed in its name and in the metaphoric maxim “an ounce of prevention is worth a pound of cure.” Yet, notwithstanding that axiom, medicinal practice and health care have been viewed, for almost a millennium, mainly as “cure,” despite always being administered with a dose of “prevention.” Now, in the 21st century, that auxiliary aspect seems to be gaining the recognition it deserves, and preventative health care has developed into a healthy market set to reach $200 billion by 2025. With a range of advanced therapeutic products in the development pipeline, including its Sol-gel delivery platform, Nature Identical™ Peptides from Caribbean blue scorpion venom that target cancer and dual gene therapies for type 2 diabetes and obesity, PreveCeutical Medical could make that market even bigger. PreveCeutical, based in Vancouver, is a health and wellness company focused on developing natural and nature identical products for the benefit of health-conscious consumers.

An update from securities research and capital markets advisory firm Crystal Equity Research provides an account of recent developments at PreveCeutical Medical (http://ibn.fm/dKLNZ). The company received an infusion of capital in June 2018 from a non-brokered private placement amounting to C$6.5 million ($4.9 million), paving the way for its R&D program to advance rapidly. The company’s lead product candidate is a non-opioid analgesic based on cannabinoids that is administered through its proprietary Sol-gel system. The Sol-gel nose-to-brain drug delivery platform delivers a therapeutic compound to a targeted site at a slow, controlled rate.

Many potentially valuable drugs for treating neurological disorders are unable to reach the brain in sufficient concentration to be therapeutically valuable because of the blood brain barrier. This is a protective membrane that protects the brain from potentially harmful foreign substances. The blood brain barrier stops some 98 percent of drug molecules from entering the brain, and so intranasal delivery of therapeutic agents is one method being employed to circumvent it in a non-invasive manner.

The Sol-gel platform allows a therapeutic agent to be administered via the nostrils, where it changes rapidly to a gel upon contact with mucosal tissue. The gel, which continues to line the nasal passage for up to seven days, slowly releases the therapeutic agent over time. It was developed in conjunction with the University of Queensland in Australia. PreveCeutical’s team in Australia recently began testing alternative spray devices for use with the Sol-gel system, and a non-disclosure agreement has been signed with one company which has a successful drug approval track record and good manufacturing standards for pharmaceutical devices.

The market for controlled-release drug delivery solutions is expected to reach $90.2 billion by 2025, according to Grandview Research, boosted by demand from several demographics. There is an increasing need for alternative drug delivery methods for seniors, on the one hand, and for pediatric patients, on the other. Administering therapeutic agents through the nasal passage is one methodology that is under active consideration at present, since it offers a non-invasive and convenient method to bypass the blood-brain barrier and deliver the agents directly to the brain. Moreover, administration via the nasal channel offers the possibility of reduced dosages, lower dosage frequency, fewer adverse gastrointestinal effects, improved patient compliance, more uniform drug effect and better overall medication efficacy.

PreveCeutical aims to be a leader in preventive health sciences and, apart from the Sol-gel project, currently has four other research and development programs, including dual gene therapy for curative and prevention therapies for type 2 diabetes and obesity; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement for highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions and other mild traumatic brain injuries.

The company also sells CELLB9®, an immune system booster. CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean blue scorpion venom.

For more information, visit the company’s website at www.PreveCeutical.com

• Significant bioavailability results were reported from LXRP’s randomized, double-blind European study that evaluated its proprietary TurboCBD capsules, powered by DehydraTECH
• Results corroborate and confirm in vitro and in vivo studies of DehydraTECH technology that measured high levels of drug delivery being achieved faster than with matching controls
• LXRP says that it is pleased that DehydraTECH has, to date, repeatedly proved evidence of success within human studies; technology earlier demonstrated ability to deliver nicotine

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is pleased to report significant bioavailability results from its randomized and double-blind European human clinical study of DehydraTECH™ powered TurboCBD™ and cannabidiol (CBD) fortified hemp oil capsules (http://ibn.fm/rPBS5). The new study evaluated the speed and degree of CBD absorption into blood plasma and included cardiovascular and cognitive enhancement in male volunteers.

Results corroborate and confirm earlier in vitro and in vivo studies that evaluated DehydraTECH’s platform and measured higher levels of drug delivery achieved quicker than controls with matching CBD amounts. LXRP said that it believes nearly identical bioavailability enhancement results would be shown if the cannabinoid was THC instead of CBD.

Based in British Columbia, Canada, LXRP is a biotechnology company that out-licenses its disruptive delivery technology to promote healthier ingestion methods. LXRP holds a patent for oral delivery of all cannabinoids and has a growing IP portfolio. DehydraTECH is its proprietary absorption technology platform.

In the six hours of the latest study, LXRP’s TurboCBD capsules delivered more CBD to the blood than the positive control capsules at each time point in the study up to its completion.

According to an article published by CFN Media Group, LXRP has applied for a patent to the USPTO, because, in lab studies, the proprietary technology may have proved itself capable of transporting active pharmaceutical ingredients (APIs) across the brain’s protective blood brain barrier (http://ibn.fm/jhx1Z).

That barrier blocks blood-borne circulating toxins and is a challenge to researchers trying to deliver APIs in medications. The barrier serves as a significant hindrance for drug treatment of diseases of the central nervous system. In lab tests, DehydraTECH was able to transport more nicotine to the brain tissue, conjugating or joining with APIs for maximum delivery.

LXRP has been conducting in vivo lab studies on animals to, in part, determine DehydraTECH’s ability to deliver enhanced levels of nicotine to the bloodstream and brain tissue. The studies found that this platform was able to deliver up to 560 percent greater amounts of nicotine to the brain tissue compared to controls without DehydraTECH. Originally, the tests were focused on developing products for nicotine replacement (http://ibn.fm/PJVMI).

These studies demonstrated that the DehydraTECH platform could effectively transport drugs, in this case nicotine, across the blood brain barrier. As a result, LXRP filed for a patent for DehydraTECH’s innovative treatment options for diseases and disorders including Alzheimer’s, Huntington’s and Parkinson’s. LXRP hopes to leverage this future possible patent to commercialize its development of future new products that treat central nervous system diseases.

For more information, visit the company’s website at www.LexariaBioscience.com

• FinCanna’s royalty finance model could be a game changer for companies needing capital while operating in the U.S. medical cannabis space
• Pilot marketing program offering HIPAA-compliant point-of-sale solution and inventory tracking system launched in California’s medical cannabis marketplace
• The U.S. medical cannabis market is projected to grow at 11.8 percent CAGR through 2025 from $5.1 billion to an estimated $12.5 billion in 2025 (New Frontier Data)

FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF), a royalty company focused on becoming the capital partner of choice for high-growth, best-in-class businesses operating in the licensed U.S. medical cannabis industry, continues to gain momentum as it invests in top-tier cannabis-related companies. FinCanna’s royalty model is a viable capital solution for U.S. businesses in the licensed medical cannabis sector as the company invests capital for a percentage of future revenues. FinCanna president and CEO Andriyko Herchak notes that the royalty model has been very successful in other industries and brings a uniquely effective approach to funding issues plaguing the U.S. cannabis marketplace.

“Our royalty model allows operators and business owners to preserve their ownership stake, not diluting themselves as they would with typical equity financing,” Herchak stated in an interview with CFN Media (http://ibn.fm/ct6xU). “Banks and federally regulated institutions are largely on the sidelines, so debt financing is difficult to find. Equity financing, as I mentioned earlier, often comes with unfavorable terms for the company. So, our royalty model fills a void in the market for companies needing capital while operating in the U.S. cannabis space.”

FinCanna’s royalty model benefits include flexibility to meet specific business needs, preservation of equity, alignment of economic interests, tax efficient protocol, timely access to capital and autonomy for the investee. FinCanna recently announced that its portfolio investee – ezGreen Compliance – is already onboarding multiple customers shortly after launching its pilot marketing program that focuses on complying with federal health privacy issues during point-of-sale and inventory procedures.

ezGreen Compliance helps its customers successfully navigate through state-by-state license, tax and compliance issues by ensuring that patients’ confidential data is being handled properly while meeting the Health Insurance Portability and Accountability Act (HIPAA) and state privacy laws, a news release states (http://ibn.fm/aWen8). ezGreen Compliance provides a proven, state-of-the-art enterprise compliance and point-of-sale software solution for licensed medical cannabis dispensaries and cultivators.

“ezGreen has made excellent progress in a very short amount of time in securing partnerships and putting itself in position to become an industry leader in the U.S. cannabis compliance category,” Herchak added. “With its proven pharma-grade compliance solution, we believe they will continue to gain momentum and establish themselves as a leader in their category.”

The FinCanna royalty portfolio includes investments in Cultivation Technologies, Inc. (“CTI”), which owns Coachella Manufacturing, one of the first companies to operate a legal solvent extraction facility for cannabis in California. CTI provides infrastructure, technology, manufacturing and branding to the legal medical cannabis industry, which includes premium medical cannabis products, concentrates and vape cartridges (http://ibn.fm/QXfeA). The company also owns six acres in Coachella, California, which is entitled for an 111,500 square foot facility featuring cultivation centers, manufacturing facilities, a testing lab, a distribution hub and a centralized processing center.

FinCanna’s third investment to date is in Refined Resin Technologies Inc., which is currently retrofitting a large, state-of-the-art medical cannabis extraction laboratory in Oakland, California. Refined Resin’s business will focus on extracting high quality cannabis distillate for white labeling services to licensed major brands and infused product manufacturers that do not have direct access to compliant production facilities (http://ibn.fm/B3nXg).

“The Refined Resin team has very deep connections in the distribution and retail markets and are themselves very effective brand developers and marketers,” Herchak noted. “Moreover, the potential capacity of the facility, and its ability to produce high value-add products bode well for the financial future of the enterprise and commensurately, outstanding value for FinCanna shareholders.”

FinCanna is building its diversified portfolio of royalty investments in scalable, best-in-class projects and companies in the U.S. medical cannabis sector, with a distinct focus on California.

For more information, visit the company’s website at www.FinCannaCapital.com

• Rising global demand for cobalt and lithium is generating interest in Marifil Mines and its resources located within South America’s famed “Lithium Triangle”
• Company recently completed four new drill holes in search for gold on secured property in Argentina’s northern Patagonian region
• Up to 600 core samples are being shipped to a certified laboratory for assay, with management optimistic about “favorable results”

Marifil Mines Ltd. (TSX.V: MFM) (OTCQB: MFMLF) is awaiting official assay results from hundreds of core samples taken during its diamond core drilling program at the San Roque property in the Rio Negro province of Argentina.

The San Roque project is jointly owned by Marifil’s wholly owned subsidiary, Marifil Mines S.A. (51 percent), and NovaGold Argentina Inc., a wholly owned subsidiary of Novagold Resources Inc. (TSX: NG) (49 percent), with Marifil serving as the project operator of the drilling campaign. The company’s primary focus is on exploring for gold, cobalt and lithium – three metals that the world is rapidly consuming and anxiously seeking (http://ibn.fm/YRf6J).

Following the successful completion of the drilling program at San Roque, there is still much yet to be done, Marifil Vice President Richard Walters stated in a news release detailing the exploration efforts (http://ibn.fm/srFWt). Walters, a certified professional geologist by the American Association of Professional Geologists and a qualified person by Canadian National Instrument 43-101, said that the company is “hopeful for some favorable results.”

The drill cores taken during Marifil’s recent campaign are undergoing geological reporting procedures to retrieve data. Core sampling, involving sawing the product in half lengthways, is underway by field crews still in place. One half of each core will be shipped to labs in Mendoza, Argentina, for assay. The company expects to ship core samples from a selection of about 600 entries that includes blanks, standards and duplicate samples to ensure a very careful and systematic quality assurance/quality control program on the drill cores.

“The drilling at our flagship asset at San Roque has been highly anticipated by the Company and its stakeholders for many years,” Marifil President and CEO Robert Abenante stated in a June 6 press release announcing the resumption of drilling at the property (http://ibn.fm/yLSe7). “Positive results at San Roque have the ability to significantly increase the fundamental value of the Company and bring the Property one step closer to being considered an economic minerals deposit.”

San Roque is located near the Atlantic coast in southwestern Argentina within an area of excellent infrastructure. It is an advanced exploration stage project involving discovery of an epithermal polymetallic deposit of sulfide minerals where gold and zinc are of principal economic focus. The property is secured by 42,320 hectares of mine rights, of which 9,449 are patented mining claims covering all known mineralization. Importantly, the mine rights are free of any non-governmental production royalties. Historical drilling on the San Roque property totals 15,837 meters with 108 holes.

Once all assays from June’s drilling campaign are reviewed by the independent laboratory and the quality assurance/quality control analysis has been completed, Marifil intends to report the results.

“This is an exciting drilling campaign, which has the potential to vividly enhance the value perception of the Property,” Walters stated in the release. “It is clear to the team of geologists that a large volume of rock is well mineralized.”

For more information, visit the company’s website at www.MarifilMines.com

• Cannabis Strategic Ventures working toward fully reporting status with SEC, OTC exchange
• Company’s portfolio includes professional staffing services, high-quality cannabis oils
• Cannabis industry expected to be responsible for more than 600,000 jobs by 2025

Cannabis Strategic Ventures, Inc. (OTC: NUGS) has pursued its mission to foster legalized cannabis industry value-adds by building a portfolio of vertically integrated companies, and now the company is preparing to uplist on the public markets by refocusing its efforts on bringing its financial reporting up to par.

“While building on our business portfolio is very important to us, bringing the Company up to fully reporting status and up listing to a higher OTC Markets tier is also a top priority,” Cannabis Strategic Ventures CEO Simon Yu stated in a recent news release (http://ibn.fm/fcMYL). “We believe it is important to provide the reliable and transparent information to our shareholders.”

The company announced on July 26 that it had finished the financial audits for fiscal years 2016 and 2017 and is now in the process of filing full financial reports and completing its audit for the fiscal year ended March 31.

As Cannabis Strategic Ventures achieves fully reporting status with the Security and Exchange Commission (SEC), it also hopes to gain greater recognition and a stronger investment base on the higher-tier exchange, which could be beneficial to current stock holders.

The company’s mission is to build a profitable enterprise in the $10 billion cannabis and $900 million hemp industries by building brands that support all facets of business operations in those markets. Within the next seven years, employment in the cannabis industry across the United States is expected to triple from 200,000 people to 630,000, according to New Frontier Data research cited by The Desert Sun (http://ibn.fm/GXYfG). The ancillary industry effect is expected to be much more widespread. In 2017, California — the leading marijuana employer state — reported 38,233 jobs directly tied to the cannabis industry and 18,165 jobs in “related” avenues, according to Arcview Market Research. Over the next three years, the cannabis industry is expected to create nearly one job for every 1,000 people in the country.

That’s encouraging news for Cannabis Strategic Ventures as it works to build on the non-cannabis employment and staffing services provided by the company’s subsidiary, Worldwide Staffing Group, Inc., in order to expand its business operations further into the cannabis staffing arena with an emphasis on the California markets. NUGS’ BudHire subsidiary provides outsourced employment service crafted to meet the needs of cannabis-related businesses by matching qualified candidates to temporary, seasonal and permanent cannabis production staffing opportunities. It also provides human resources consulting and other professional employment services to the cannabis industry.

Pure Applied Sciences Inc., another of the company’s subsidiaries, produces high-quality cannabis oils that conform with good manufacturing practices protocols (cGMP) and the guidelines for active pharmaceutical ingredients (API) in the United States. The oils are marketed under its PureOrganix brand.

For more information, visit the company’s website at www.CannabisStrategic.com

• Asphalt Ridge processing and extraction facility debuts
• Cost-effective technology set to unlock 87 million BOE
• Formal application submitted to Nasdaq

There are oil and gas companies and there are tech companies, and, while Petroteq Energy Inc. (TSX.V: PQE) (OTC: PQEFF) may be a bit of both, this is a corporation focused more on the high-margin commercialization of its licensing technology than its oil commodities business. The company has developed an environmentally safe, continuous flow, closed loop technology – the first in North America and probably the world – that is capable of extracting bitumen from oil sands. It recently commissioned a processing and extraction plant at Asphalt Ridge in the Uintah Basin of Utah that will, initially, have the capacity to produce 1,000 barrels per day of bitumen. Although it will generate cash flow from the endeavor, Petroteq expects to get the bulk of its future revenues from licensing its innovative oil sands technology.

The Petroteq technology is the result of almost five years of scholarship by the company’s research and engineering teams, led by its chief technology officer, Dr. Vladimir Podlipskiy. It’s technology that’s safe for the environment, depending on a patented solvent/surfactant that produces no greenhouse gases. It’s also safe to produce, since it requires no high temperatures or pressures. The technology can be effectively applied to both “water-wet” deposits, such as the oil sands projects in Alberta, Canada, and in the 20 or so countries around the globe with oil sands, as well as the “oil-wet” deposits found in Utah, where the company has its extraction facility.

Petroteq’s patented Liquid Extraction System is also cost-effective in the current oil market, producing a barrel of oil equivalent (BOE) at around $22.00. It is set to unlock an estimated 87 million BOE at Asphalt Ridge and could find application extracting Utah’s 32 billion BOE. The company plans to license the technology globally. Its proof-of-concept is the extraction plant at Asphalt Ridge.

Petroteq’s Temple Mountain Mine mineral lease at Asphalt Ridge covers over 2,500 acres in northeastern Utah, with an estimated 139.5 million gross barrels of bitumen, as disclosed in an independent resource evaluation report prepared by Chapman Petroleum Engineering Ltd. in 2015 in accordance with the Canadian Oil and Gas Evaluation Handbook (COGEH). Of this gross volume of bitumen in place, Chapman estimated that 87.8 million barrels would, under favorable circumstances, support very positive mining economics. These 87.8 million barrels would be classified as a “Contingent Resource” under current NI 51-101 and COGEH criteria.

Petroteq’s environmentally friendly heavy oil processing and extraction plant located at Asphalt Ridge debuted in June (http://ibn.fm/rPHAJ). The initial goal is to get up to a capacity of 1,000 barrels per day very soon. Thereafter, subject to having sufficient capital, Petroteq’s goal is for the plant to produce as much as 2,000 barrels of oil per day (BOD) by year-end 2019 and 5,000 BOD by year-end 2020.

In July, Petroteq announced that it had submitted an application to have the company listed on the Nasdaq Capital Market (http://ibn.fm/L07c7).

“We believe up-listing in the U.S. from the OTC Market to the NASDAQ Capital Market will increase awareness of Petroteq in the financial community,” David Sealock, CEO of Petroteq, stated in a news release. “We believe that a NASDAQ listing will help unlock some of the shareholder value we are trying to create for our stakeholders. A NASDAQ listing should provide us with more liquidity and a larger pool of investors that use the NASDAQ Stock Market as a requirement for assembling portfolio.”

For more information, visit the company’s website at www.Petroteq.energy

• CBD division offers potential for shareholders, as shared on MoneyTV
• Over 70 retail establishments offering ChineseHempOil.com products in Los Angeles
• Ground work for wholly owned subsidiary focused on CBD products began in 2016
• Continued commitment to cryptocurrency education for the Chinese-speaking community worldwide

ChineseInvestors.com, Inc. (OTCQB: CIIX), a company focused on providing financial information and services to the Chinese-speaking community worldwide, will soon spin off its cannabis-related products into the wholly owned subsidiary ChineseHempOil.com, Inc. The spinoff was originally scheduled for May 31, 2018, but was temporarily postponed as CIIX continues to develop domestic sales channels.

CEO Warren Wang joined Donald Baillargeon on MoneyTV to discuss CIIX’s CBD division and share new developments and the potential that this investment has for shareholders (http://ibn.fm/U1SXy). This new subsidiary has two offices, one in China focused on cosmetics and CBD infusion and the other in Los Angeles, California, selling CBD oil for Chinese consumers. In the interview, Wang highlighted CIIX’s three divisions as being centered on hemp oil, Chinese investors and cryptocurrency. The focus of the conversation was on the unique opportunity in which the hemp oil division is positioned. Wang stated, “My idea is to spin off the hemp oil division hopefully by end of the year.” The full interview can be found at www.MoneyTV.net.

Though Wang describes CBD products and education as personal passions, the company is too diversified to focus all of his attention in that direction. CIIX is the first company to educate the Chinese consumer on the benefits of CBD, starting first in the U.S. and then expanding. Whether the conversation is around CBD, cryptocurrency or investing, CIIX remains dedicated to providing the best education available to Chinese-speaking investors.

Earlier this year, CIIX appointed Nina Wang as vice president of sales for U.S. consumer retail/e-commerce. Through her efforts, ChineseHempOil.com has developed strategic relationships with over 70 retail establishments in the Los Angeles area. Plans are in place to expand product placement into Northern California, furthering the process to complete the spin-off of all hemp-related assets (http://ibn.fm/qpAWQ). Wang stated in his interview with MoneyTV that the goal for the next year, in addition to the successful spin-off, is to increase brand awareness.

The company first started laying the groundwork to capitalize on the growing demand for cannabidiol-based nutrition and health products in 2016. In 2017, ChineseCBDoil.com was launched, offering the first online CBD health product store in the Chinese language. Soon after, a ‘Yelp’ style social media application available in the Apple App Store was launched as a database of marijuana dispensaries and cannabis strains to provide consumers with a database of reviews and locations. The planned spinoff of such assets will allow CIIX to focus on its new cryptocurrency division and its core financial education division while simultaneously allowing ChineseHempOil.com to expand within the rapidly growing cannabis industry.

CIIX is committed to cryptocurrency education for the Chinese-speaking community. The company provides education opportunities by broadcasting daily videos from the NYSE titled ‘Bitcoin MultiMillionaire,’ broadcasting the television program ‘Bitcoin Talk Show’ with a reach of over 500,000 Chinese people in North America, redistributing Chinese translations of The Bad Crypto Podcast and offering cryptocurrency trading courses online in both English and Chinese through its newly established Bitcoin Trading Academy LLC. These are just some of the strategic ways in which CIIX has set itself apart as the leading financial information website for Chinese-speaking investors globally.

For more information, visit the company’s website at www.ChineseInvestors.com